Large-cap Health Care company Biogen has moved 0.6% so far today on a volume of 221,707, compared to its average of 1,000,512. In contrast, the S&P 500 index moved 0.0%.
Biogen trades -22.78% away from its average analyst target price of $320.47 per share. The 30 analysts following the stock have set target prices ranging from $239.0 to $500.0, and on average have given Biogen a rating of buy.
Anyone interested in buying BIIB should be aware of the facts below:
-
Biogen's current price is 63.1% above its Graham number of $151.77, which implies that at its current valuation it does not offer a margin of safety
-
Biogen has moved -15.5% over the last year, and the S&P 500 logged a change of 15.0%
-
Based on its trailing earnings per share of 10.07, Biogen has a trailing 12 month Price to Earnings (P/E) ratio of 24.6 while the S&P 500 average is 15.97
-
BIIB has a forward P/E ratio of 15.8 based on its forward 12 month price to earnings (EPS) of $15.68 per share
-
The company has a price to earnings growth (PEG) ratio of 109.47 — a number near or below 1 signifying that Biogen is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 2.48 compared to its sector average of 4.08
-
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
-
Based in Cambridge, the company has 8,725 full time employees and a market cap of $35.86 Billion.